Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report $1.47 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Crispr Therapeutics’ earnings, with estimates ranging from $500,000.00 to $2.00 million. Crispr Therapeutics posted sales of $3.58 million in the same quarter last year, which suggests a negative year over year growth rate of 58.9%. The business is scheduled to report its next earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $13.09 million for the current fiscal year, with estimates ranging from $2.90 million to $24.00 million. For the next fiscal year, analysts expect that the business will report sales of $56.80 million per share, with estimates ranging from $22.50 million to $91.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Crispr Therapeutics.
Get Crispr Therapeutics alerts:Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. Crispr Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The firm had revenue of $1.36 million during the quarter, compared to analysts’ expectations of $3.64 million. During the same quarter last year, the company posted ($0.54) EPS. The company’s quarterly revenue was down 49.6% compared to the same quarter last year.
CRSP has been the subject of several analyst reports. Chardan Capital lifted their price target on shares of Crispr Therapeutics from $25.00 to $72.50 and gave the stock a “buy” rating in a research report on Tuesday, May 15th. ValuEngine upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. TheStreet upgraded shares of Crispr Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, March 16th. Zacks Investment Research upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, BidaskClub cut shares of Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 5th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Crispr Therapeutics has an average rating of “Buy” and an average target price of $65.90.
In related news, CEO Samarth Kulkarni sold 15,000 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $69.36, for a total transaction of $1,040,400.00. Following the transaction, the chief executive officer now owns 163,560 shares of the company’s stock, valued at approximately $11,344,521.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Rodger Novak sold 75,000 shares of Crispr Therapeutics stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $60.00, for a total transaction of $4,500,000.00. Following the transaction, the president now directly owns 1,183,247 shares in the company, valued at approximately $70,994,820. The disclosure for this sale can be found here. Insiders have sold a total of 1,510,845 shares of company stock worth $80,447,023 in the last three months. 37.70% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. EAM Global Investors LLC bought a new position in Crispr Therapeutics in the first quarter valued at approximately $1,089,000. CIBC World Markets Inc. bought a new position in Crispr Therapeutics in the first quarter valued at approximately $1,156,000. Royal Bank of Canada lifted its stake in Crispr Therapeutics by 91.9% in the first quarter. Royal Bank of Canada now owns 26,620 shares of the company’s stock valued at $1,217,000 after buying an additional 12,751 shares in the last quarter. Hilltop Holdings Inc. bought a new position in Crispr Therapeutics in the first quarter valued at approximately $919,000. Finally, LPL Financial LLC bought a new position in Crispr Therapeutics in the first quarter valued at approximately $256,000. 39.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:CRSP traded up $0.33 during trading on Wednesday, hitting $63.21. 846,500 shares of the company’s stock were exchanged, compared to its average volume of 1,352,314. Crispr Therapeutics has a 1-year low of $15.67 and a 1-year high of $73.90. The stock has a market cap of $2.97 billion, a price-to-earnings ratio of -36.96 and a beta of 4.22.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment